A Study of Neoadjuvant/adjuvant Durvalumab for the Treatment of Patients with Resectable Non-small Cell Lung Cancer - AEGEAN

Exclusion Criteria

• - History of allogeneic organ transplantation
• - Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease, diverticulitis, systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome)
• - History of another primary malignancy
• - History of active primary immunodeficiency
• - Active infection including tuberculosis hepatitis B and C, or human immunodeficiency virus
• - Deemed unresectable NSCLC by multidisciplinary evaluation
• - Patients who have pre-operative radiotherapy treatment as part of their care plan
• - Patients who have brain metastases or spinal cord compression
• - Stage IIIB N3 and Stages IIIC, IVA, and IVB NSCLC
• - Known allergy or hypersensitivity to any of the study drugs or excipients
• - Existence of more than one primary tumour such as mixed small cell and NSCLC histology
• - Patients whose planned surgery at enrollment includes any of the following procedures: pneumonectomy, segmentectomies, or wedge resections
• - Patients with a documented test result confirming the presence of EGFRm or ALK translocation